Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.See webinar details
Prof. Chantal Mathieu KU Leuven, Belgium2 Talks
Chantal Mathieu attended the Catholic University of Leuven, where she obtained her medical degree as well as her PhD. She is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research. Her work in animal models of type 1 diabetes established 1,25-dihydroxyvitamin D3... read moreas an immune modulator and demonstrated the potential of Lactococcus Lactis as a carrier tool for peptides and proteins, which became the basis for a worldwide clinical trial in people with newly diagnosed type 1 diabetes. Her research group was amongst the first to demonstrate the relevance of post-translational modifications of beta-cell peptides and proteins in autoantigen generation in murine and human type 1 diabetes. C. Mathieu’s clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes. She leads the INNODIA project and established its Patient Advisory Committee. C. Mathieu is also (senior) vice-president of EASD, Chair of postgraduate education and Chair of the European Diabetes Forum.